Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation

International Journal of Hematology

Volumn 91, Issue 1, 2010, Pages 128-131

  Gotoh, Moritaka ^a   Tauchi, Tetsuzo ^a   Yoshizawa, Seiichiro ^a   Kitahara, Toshihiko ^a   Kiguchi, Toru ^a   Kimura, Yukihiko ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

BCR ABL mutations; Chronic myeloid leukemia; Dasatinib; Stem cell transplantation

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CREATININE; CYTARABINE; DALTEPARIN; DASATINIB; DAUNORUBICIN; FLUDARABINE; HYDROXYUREA; IMATINIB; MELPHALAN; NILOTINIB; TACROLIMUS; URSODEOXYCHOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TRANSFUSION; CANCER RADIOTHERAPY; CASE REPORT; CHIMERA; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; CORD BLOOD STEM CELL TRANSPLANTATION; CREATININE BLOOD LEVEL; EDEMA; FEVER; GENE MUTATION; HUMAN; MALE; NEUTROPHIL COUNT; PANCYTOPENIA; PLEURA EFFUSION; RADIATION DOSE; RASH; REAL TIME POLYMERASE CHAIN REACTION; SHORT TANDEM REPEAT; THROMBOCYTE COUNT; TREATMENT RESPONSE; VEIN OCCLUSION; WHOLE BODY RADIATION;

BLAST CRISIS; CORD BLOOD STEM CELL TRANSPLANTATION; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 75049083078     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0466-3     Document Type: Article

References (11)

1. JM Goldman 2007 How I treat chronic myeloid leukemia in the imatinib era Blood 110 2828 2837 10.1182/blood-2007-04-038943 1:CAS:528:DC%2BD2sXht1SmurfI 17626839 (Pubitemid 350006935)
2. A Shimoni M Leiba M Schleuning, et al. 2009 Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemia Leukemia 23 190 194 10.1038/leu.2008.160 1:CAS:528:DC%2BD1MXkvVeisg%3D%3D 18596746
3. M Yamamoto K Kakihana K Ohashi, et al. 2009 Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR Int J Hematol 89 482 488 10.1007/s12185-009-0290-9 1:CAS:528:DC%2BD1MXltFWmurg%3D 19343480
4. A Tojo K Usuki A Urabe, et al. 2009 A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or-intolerant Ph + CML or relapsed/refractory Ph + ALL Int J Hematol 89 679 688 10.1007/s12185-009-0327-0 1:CAS:528:DC%2BD1MXms1Kks78%3D 19449194
5. D Marin D Milojkovic E Olavarria, et al. 2008 European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood 112 4437 4444 10.1182/blood-2008-06-162388 1:CAS:528:DC%2BD1cXhsVCltbzF 18716134
6. T O'Hare CA Eide MW Deininger 2008 New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check Export Opin Investig Drugs 17 865 878 10.1517/13543784.17.6.865 (Pubitemid 351864324)
7. Milojkovic D, Bua M, Apperley JF, et al. Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival. ASH Abstracts. 2008; Abst 332.
8. O Ottmann H Dombret G Martinelli, et al. 2007 Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood 110 2309 2315 10.1182/blood-2007-02-073528 1:CAS:528:DC%2BD2sXhtFCnsbzK 17496201 (Pubitemid 47523149)
9. R García-Muñoz A Galar C Moreno, et al. 2007 Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825) Leuk Lymphoma 48 2461 2464 10.1080/10428190701671044 18067026 (Pubitemid 350253483)
10. S Redaelli R Piazza R Rostagno, et al. 2009 Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants J Clin Oncol 20 469 471
11. Breccia M, Palandri F, Iori AP, et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res. 2009; 28. (ahead of print) doi: 10.1016/j.leukres.2009.04.036.